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Key Points 
 
 
• Hdac1 and to a lesser extent Hdac2 behave as oncosuppressors during tumor 
initiation, while they work as oncogenes in tumor maintenance. 
• Class I HDAC inhibitors (VPA) accelerate tumorigenesis in murine models of 
leukemia, that suggests caution in their clinical use. 
 
Abstract 
Aberrant recruitment of histone deacetylases (HDACs) by the oncogenic fusion 
protein PML-RAR is involved in the pathogenesis of acute promyelocytic leukemia 
(APL). PML-RAR, however, is not sufficient to induce disease in mice, but requires 
additional oncogenic lesions during the pre-leukemic phase. Here, we show that 
knock-down of Hdac1 and Hdac2 dramatically accelerates leukemogenesis in 
transgenic pre-leukemic mice. These events are not restricted to APL, since 
lymphomagenesis driven by deletion of p53, or to a lesser extent by c-myc 
overexpression, was also accelerated by Hdac1 knock-down. In the pre-leukemic 
phase of APL Hdac1 counter-acts the activity of PML-RAR in: i) blocking 
differentiation, ii) impairing genomic stability and iii) increasing self-renewal in 
hematopoietic progenitors as all of these events are affected by the reduction in Hdac1 
levels. This led to an expansion of a subpopulation of PML-RAR expressing cells that 
is the major source of leukemic stem cells in the full leukemic stage. Remarkably, 
short-term treatment of pre-leukemic mice with an HDAC inhibitor accelerated 
leukemogenesis. In contrast, knock-down of Hdac1 in APL mice led to enhanced 
survival of the leukemic animals. Thus, Hdac1 has a dual role in tumorigenesis: 
oncosuppressive in the early stages, and oncogenic in established tumor cells. 
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Introduction 
 
Epigenetic alterations are considered as relevant as genetic mutations in 
tumorigenesis1. Small molecules that inhibit the activity of epigenetic enzymes have 
the potential to revert those changes, and have entered clinical use, validating the 
concept of epigenetic therapy2. As an example, HDAC inhibitors (HDACi) that target 
multiple HDACs with non-redundant functional roles in normal and tumor cells3,4 are 
effective for the treatment of cutaneous T cell lymphoma2. Epigenetic drugs, 
however, have single agent efficacy only in selected hematological malignancies, 
underlying the need for optimized drugs/treatment strategies2. Initial genetic 
dissection of the role of specific HDACs in murine models has revealed that 
inactivation of Hdac1 and Hdac2 results in hematopoietic defects, and gene deletion 
in established tumor cells results in loss of proliferation and/or decreased survival5,6. 
Indeed, the development of class I (HDACs 1, 2, 3 and 8)-selective HDACi such as 
the Food and Drug Administration (FDA)-approved compound romidepsin, supports 
the proposed pro-oncogenic role of class I HDACs7,8. 
APL is caused by the fusion protein PML-RAR9 and expression of PML-RAR in 
murine hematopoietic progenitors leads to APL that reflects the human disease10. 
Prior to full leukemic transformation PML-RAR induces a “pre-leukemic” stage 
without an overtly dramatic phenotype that leads to substantial alterations in the self-
renewing properties of the pre-leukemic cells11,12. It is assumed therefore that PML-
RAR is necessary but not sufficient to cause APL, and additional genetic hits, largely 
unknown, must occur for the clonal expansion of leukemic blasts. 
Different HDAC-containing complexes associate with PML-RAR. These complexes 
(such as NURD and SMRT/NCoR) include Class I HDACs13. Through its association 
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with HDACs, PML-RAR is able to transcriptionally silence its target genes and to 
regulate the stability of the oncosuppressor p5314. In view of these observations, we 
functionally assessed the role of individual HDACs, in this case Hdac1/2, in APL 
development and progression. 
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Methods 
 
Mice 
Transgenic mCGPR/PR mice were generously provided by T.J. Ley (Washington 
University, St Louis) and backcrossed into the C57BL/6J strain. C57BL/6J p53-/- mice 
were obtained from the Jackson Laboratory. Eμ-myc transgenic mice were kindly 
provided by Dr Jerry Adams (Walter and Eliza Hall Institute, Melbourne, Australia)15. 
For lin- transplantation experiments, lethally irradiated C57BL/6J mice, 12 to 14 
weeks old, were inoculated intravenously with 300.000 GFP+-transduced lin– cells, 
together with 500.000 spleen cells obtained from a WT mouse16. For leukemia 
transplantation, GFP+ transduced leukemic cells were injected intravenously (200.000 
cells/mouse) in syngeneic recipient mice. APL leukemias used for Hdac1 knockdown 
experiments shown in figure 5 have been described previously 16. For the generation 
of Eμ-myc lymphomas knocked-down for Hdac1 and Hdac2, fetal livers were 
harvested from E13.5-E15.5 Eμ-myc embryos (in the C57BL/6/CD45.2 strain) and 
transduced with pLMSshRNAmiR30.SCR, pLMSshRNAmiR30.Hdac1 or 
pLMSshRNAmiR30Hdac2 constructs as detailed previously17,18. Irradiated recipient 
P T P R C A / C D 4 5 . 1  m i c e 19 were injected with unsorted fetal liver cells (1x106 
GFP+ per mouse) and sacrificed once lymphoma developed at which point lymph 
nodes, spleen and thymus were harvested and stored in liquid nitrogen for further 
analysis. Animals were checked periodically for clinical signs of disease (by 
inspection, and periodical blood analysis using the AcT™ 5diff Beckman Coulter, 
Brea, CA, USA). Long term reconstitution of the hematopoietic compartment was 
assessed by scoring percentage of GFP+ cells in peripheral blood at least four months 
after transplantation. Mice were sacrificed by CO2 inhalation when they became 
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detectably ill. The survival rate was calculated using the Kaplan-Meier method. All 
procedures involving animals were done in accordance with national and international 
laws and policies.  
 
Purification of lin- cells and infection procedures 
Lin- cells from WT C57BL/6J or transgenic mCGPR/PR mice and APL blasts from 
leukemic animals were obtained and maintained as previously described16. Cells were 
infected using the viral supernatants (see below), and then sorted by GFP positivity 
(FACSAria, Becton Dickinson, Franklin Lakes, NJ, USA16).  
Eμ-myc fetal liver cells were grown in high-glucose Dulbecco modified Eagle 
medium (DMEM) supplemented with 10% fetal calf serum, penicillin (100 
U/mL)/streptomycin (100 mg/mL), 0.1 mM L-asparagine, 50 mM 2-mercaptoethanol, 
recombinant IL-3 (2ng/mL), IL-6 (2ng/mL) and SCF (10ng/mL) (all cytokines from 
PeproTech).  
 
Retroviral shRNA constructs and virus production 
ShRNA-based retroviral plasmids (used for the experiments with pre-leukemic, 
leukemic and p53 null cells) were generated by ligating synthetic oligonucleotides 
targeting the indicated mRNAs into a modified pRETRO-SUPER vector20 in which 
the cDNA for puromycin selection had been replaced with that encoding for EGFP. 
The shRNA sequences (supplemental Table 4) are in the format: target sequence 
sense (underlined)-loop-target sequence antisense (underlined). 
The pRETRO-SUPER vectors and package plasmid pCL-Eco were co-transfected 
into packaging ecotropic Phoenix cells, and the viral supernatants were produced as 
previously described16.  
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Targeting sequences for shRNA-miR30 constructs (used for the experiments with Eµ-
myc cells) were identified using the previously described DSIR algorithm21. The top 
ranked short hairpin (shRNAs) were used to create 10 miR30 sequences (97mer, 
Sigma-Aldrich) and these were cloned into the pLMS vector following generation of 
approximately 110bp shRNA-miR30’s by amplification of 97mers using 5′mir30-
XhoI (CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG) and 
5’miR30-EcoRI (CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA) 
primers. The miRNA oligomer sequences (supplemental Table 4) are in the format: 
mir-30 context-sense (underlined)-loop-antisense (underlined). Viral supernatants 
were produced as previously described 17,18. Knock-down regulation of gene 
expression can be associated to experimental artefacts, due to off-target effects22. We 
can exclude that off-target effects confound the interpretation of our results, for the 
following reasons: a) the use of different sequences to interfere with Hdac1 
expression, both in vivo and in vitro, gave identical results; b) the in vitro Hdac1 
knock-down phenotype (potentiation of differentiation block and enhancement of 
colony forming ability) was rescued by re-expressing a non-interferable Hdac1 
protein in lin- cells; c) the in vivo pharmacological inhibition of HDACs recapitulates 
the observed Hdac1 knock-down phenotype. 
 
Cell lines 
Human APL NB4 cells were grown in RPMI supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, and antibiotics. Phoenix cells were purchased from ATCC 
and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, and antibiotics. Cultures were maintained in a 
humidified tissue culture incubator at 37°C in 5% CO2. 
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Immunoblots and Antibodies 
Whole cell extracts were obtained by lysis in SDS buffer (50 mM Tris HCl, 10% 
glycerol, 2% SDS). Proteins were separated by SDS-PAGE, blotted onto PVDF 
membrane and probed with the indicated antibodies. For determination of p53 status 
of Eμ-myc lymphomas, 1.5x106 FACS-sorted GFP+ tumour cells were exposed to 
10Gy irradiation and incubated at 37oC in 10% CO2 for 1 hour alongside non-
irradiated controls and then lysed. The antibodies used in the study were: anti-Hdac1 
(ab7028), anti-Hdac2, (ab7029), anti-HDAC3 (ab7030), anti-H4-Ac K5 (ab51997) 
and anti-H3 (ab1791) (Abcam, Cambridge, UK); anti-RARα (sc-551) (Biotechnology 
Inc., Santa Cruz, CA, USA); anti-Acetylated histone H3 and H4 were detected using a 
home-made antibody23; anti-p53 (Novacastra, NCL-p53-505), anti-p19ARF (Santa 
Cruz sc32748), anti-Hsp90 (Stressgen ADI-SPA-830) and anti-β-actin (Sigma 
Aldrich). 
 
Differentiation, serial replating and cytogenetic assays 
Five thousands sorted lin- cells were plated in methylcellulose medium (MethoCult™ 
SF M3236, Stem Cell Technology, Vancouver, BC, Canada) containing 15% FCS, 
2ng/ml IL3, 2ng/ml IL6, 50ng/ml SCF, 60ng/ml G-CSF and 20ng/ml GM-CSF 
(Peprotech, Rocky Hill, NJ USA). After 7-10 days of culture, colonies were scored 
and the cells used for immunolabeling, serial replating experiments and 
morphological analysis16. 
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Analysis of mitotic chromosome spreads 
Lin- cells were plated in methylcellulose medium as previously described. After 4 
days, cells were harvested and resuspended in RPMI medium containing 10% fetal 
calf serum, 20ng/ml IL3, 20ng/ml IL6, 100ng/ml SCF and 0.1μg/ml of colcemid 
(Gibco, Life Technologies Europe Monza, Italy). After four hours, cells were washed 
and resuspended in hypotonic buffer (0,075M KCl), incubated for 1 hr at 37°C and 
then fixed with methanol/acetone (3:1). Cells were spotted on glass slides and stained 
with Giemsa (Sigma-Aldrich, St Louis, MO, USA). Metaphases were analyzed by 
optical microscopy. 
 
In vivo BrdU incorporation 
BrdU incorporation was analyzed by fluorescence-activated cell sorting analysis (BD, 
FACSCantoII BD, FACSDiva Software V6.1.1, Becton Dickinson, Franklin Lakes, 
NJ, USA) after four hours of a single intraperitoneal (IP) injection of BrdU 
(40mg/Kg) using the FITC BrdU Flow Kit (BD).  
 
Immunophenotyping and histopathological analysis  
Fluorescence activated cell sorting (FACS) analysis (BD, FACSCantoII BD, 
FACSDiva Software V6.1.1) was performed on splenocytes and bone marrow cells 
derived from transplanted mice. Cells derived from healthy mice were used as 
control. The antibodies used for the immunophenotyping were: Ly-6A/E (SCA1) PE-
Cy5.5 conjugated, CD117 (C-Kit) APC conjugated, anti mouse CD45.2 FITC 
conjugated, CD11b (MAC1), Ly-6G (Gr-1), CD3e, CD45R (B220) all PE-Cy7 
conjugated (eBioscience, San Diego, CA, USA). Blood smears and cytospins were 
stained using the May-Grünwald-Giemsa method (Sigma-Aldrich).  
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Pharmacological treatments  
Preleukemic six-eight weeks old mCGPR/PR mice were intraperitoneally injected with 
VPA (Sigma) dissolved in PBS at the dose of 400 mg/kg twice a day for 14 days.  For 
differentiation analysis, twelve hours after the last injection the mice were sacrificed 
and bone marrow cells were analyzed by FACS for surface differentiation markers or 
plated in methylcellulose as described. For in vivo experiments, the mice were 
followed until leukemia development. For APL mice treatment, 2*10^5 APL cells 
were injected intravenously into non-irradiated congenic recipient mice (C57Bl/6-
Ly5.1) and then treated with VPA (intraperitoneally at the dose of 400 mg/kg twice 
a day for 4 weeks) when the blast cells (Ly5.2) in peripheral blood reached 5–10%24.  
 
Quantitative PCR 
Total RNA was purified using RNeasy Mini Kit (Qiagen, Valencia, CA), quantified 
and reverse transcribed. Five-ten ng of cDNA were used to perform quantitative PCR 
(qPCR) using SYBR Green Reaction Mix (Perkin Elmer, Boston, MA). mRNA levels 
were normalized against GAPDH mRNA. The sequences of the primers used in this 
study are listed in supplemental Table 4.  
 
Statistical Analysis 
Statistical analyses were performed using unpaired samples two tails t test (Graphpad 
software) unless otherwise specified. Statistical analysis of the Kaplan-Meier survival 
curves were done using the logrank test (Prism 4.0 software). 
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Results 
 
Hdac1/ Hdac2 knock-down accelerates APL development  
As a model system for PML-RAR-driven APL we used the well-characterized 
mCGPR/PR mouse model12. Lineage-negative (lin-) cells enriched in hematopoietic 
stem cells (HSCs) and progenitors from mCGPR/PR mice16 were transduced with GFP-
tagged retroviral vectors targeting Hdac1 or the control (CTRL) firefly luciferase 
transcripts. FACS-purified GFP+/lin- cells were then analyzed in vitro and in vivo 
(supplemental Figure 1). RNA and protein analysis confirmed a strong reduction of 
Hdac1 by the targeting shRNA constructs (Figure 1A, supplemental Figure 2) with a 
compensatory increase in the expression of Hdac2 but not Hdac3 (Figure 1A) as 
previously reported6,25. In addition, we observed increased acetylation of histone H4 
at lysine 5, that is preferentially de-acetylated by Hdac125,26, while global histone 
acetylation remained relatively unchanged  (Figure 1A). Knock-down of Hdac1 had 
no effect on the expression of PML-RAR (supplemental Figures 3, 4).  
Reconstitution of irradiated syngeneic recipient mice with GFP+/lin-/Hdac1 
knockdown (Hdac1-kd) cells led to a dramatic shortening of leukemia onset compared 
to controls (Figures 1B, supplemental Table 1A) and knock-down of Hdac1 was 
maintained in leukemias derived from these mice (Figures 1C, supplemental Figure 
5). Interestingly, the up-regulation of Hdac2 observed in freshly transduced cells was 
not maintained in leukemic blasts (Figure 1C).  CTRL and Hdac1-kd leukemias were 
essentially indistinguishable macroscopically, histologically and cytologically (Figure 
1D, supplemental Figures 6A-B). In contrast, immunophenotypic analysis revealed a 
greater proportion of immature Gr-1+/c-Kit+/Hdac1-kd cells (Figure 1E, supplemental 
Table 2). Transplantation of primary Hdac1-kd or CTRL APLs into syngeneic 
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recipients resulted in the development of secondary leukemias at similar rates 
(supplemental Figure 7) indicating that Hdac1 knock-down mainly affects the pre-
leukemic stage.  
Similar studies were performed using shRNA vectors targeting Hdac2. Western blot 
analysis of transduced GFP+/lin-/Hdac2-kd cells confirmed decreased Hdac2 
expression with little concomitant increase in Hdac1 levels, suggesting that the 
modality of regulation of Hdac1 and Hdac2 differs (supplemental Figure 8A). Knock-
down of Hdac2 led to a significant acceleration of APL development (supplemental 
Figure 8B), though less pronounced than Hdac1 knock-down (supplemental Figure 
8C) and APL cells from these mice maintained decreased Hdac2 expression 
(supplemental Figure 8D). Interestingly, while Hdac1 levels were generally 
unchanged, in one case (n. 10) we observed a strong reduction of Hdac1 levels in 
leukemic cells, hinting at a potentially cooperating oncosuppressive role for Hdac1 
and Hdac2 (supplemental Figure 8D).  
Expression analysis of a collection of primary human APL samples and controls 
normal CD34+ progenitor cells showed that Hdac1 and Hdac2 transcript levels were 
reduced in APL (supplemental Figures 9A-B). To further validate this observation, we 
surveyed the expression levels of Hdac1 and Hdac2 in primary human AML samples 
from available gene profiling datasets27. Interestingly, Hdac1 mRNA levels were 
selectively reduced in primary APL samples, compared to other AML subtypes, and 
relative to normal progenitor CD34+ cells and normal promyelocytes (supplemental 
Figure 9C). Hdac2 levels were also down-regulated compared to normal CD34+ cells 
in several AML subtypes, though during normal myeloid differentiation there is a 
strong decrease in expression in promyelocytes (supplemental Figure 9D). 
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Collectively, these results support a potential oncosuppressor role, at least of Hdac1, 
in human APL. 
 
Hdac1 behaves as a general oncosuppressor 
To determine if accelerated tumorigenesis following knock-down of Hdacs 1 or 2 was 
restricted to APL, we performed additional knock-down experiments in two different 
murine lymphoma models. We firstly examined the role of Hdac1 and 2 on 
spontaneous lymphomogenesis occurring in p53-/- mice28. After transduction with the 
Hdac1- or 2-targeting vectors, lin- cells derived from p53-/- mice were transplanted 
into syngeneic, lethally irradiated mice (Figure 2A-B). All transplanted animals 
developed thymic lymphomas, and knock-down of Hdac1 significantly accelerated 
lymphomagenesis (Figure 2B left panel, supplemental Table 1B). Hdac2 knock-down, 
in contrast, did not result in a significant change in survival of the mice (Figure 2B 
right panel, supplemental Table 1B), suggesting that the oncosuppressive functions of 
Hdac1 and Hdac2 may be context-dependent.  
We then investigated a role for Hdac1 and 2 in the context of c-myc overexpression 
utilizing the Eμ-myc mouse15. Eμ-myc fetal liver hematopoietic progenitor cells were 
transduced with retroviruses expressing shRNAs targeting Hdacs 1 or 2. Unsorted 
cells were transplanted into irradiated recipient mice and tumor development was 
monitored (Figure 2C, supplemental Table 1C). Consistent with the data outlined 
above, knock-down of Hdac1 hastened the rate of myc-induced lymphomagenesis 
while the effects of Hdac2 knockdown was considerably more modest and did not 
achieve statistical significance (Figure 2C, supplemental Table 1C). GFP+ tumors 
isolated from Eμ-myc/Hdac1-kd and Eμ-myc/Hdac2-kd mice showed robust and 
specific knock-down of the targeted protein (Figure 2D). Moreover, we tested these 
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tumors for maintenance of a p53 response and observed the p53 pathway to be 
functionally intact as demonstrated by γ-irradiation-induced upregulation of p53 and 
constitutively low expression of p19ARF which is utilised as surrogate marker for wild 
type p53 expression in this model29 (supplemental Figure 10). Finally, sequence 
analysis of p53 revealed it to be wild type in all Eμ-myc/Hdac1-kd and Eμ-
myc/Hdac2-kd tumors (data not shown). These data suggest that Eμ-myc tumors with 
loss of Hdac1 or 2 develop in a manner that maintains expression of wild type p53. 
Taken together, these data extend our initial findings in APL, and indicate a more 
general oncosuppressive role for Hdac1. 
 
Hdac1 knock-down enhances differentiation block and genomic instability of 
PML-RAR expressing cells  
APL is characterized by a block in myeloid differentiation and alteration of genomic 
stability30,31. Both events are supposedly driven by the direct action of PML-RAR, 
and at least in part this is due to its association with Hdacs32, although Hdacs can 
affect both biological processes independently of PML-RAR33,34. We therefore 
investigated whether Hdac1 knock-down affected either or both of these processes in 
the pre-leukemic setting to accelerate PML-RAR-driven APL. As previously 
shown16,35, expression of PML-RAR in the pre-leukemic phase caused a modest 
defect on differentiation in vitro (supplemental Figure 11), and Hdac1 knock-down 
greatly augmented this effect with a strong decrease of Mac-1+ cells, and an increase 
of c-Kit+, immature cells (Figure 3A-B). Interestingly, this phenomenon was PML-
RAR-dependent, since Hdac1 knock-down in wild-type lin- cells did not significantly 
affect differentiation (supplemental Figure 12). PML-RAR expression results in an 
enhanced proliferative ability of lin- cells35 and consistent with the observed 
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potentiation of the differentiation block, Hdac1 knock-down led to a further increase 
in the proliferative potential of PML-RAR expressing lin- cells, as demonstrated by 
the higher number of colonies recovered in serial re-plating experiments (Figure 3C). 
We next determined the effect of Hdac1 knock-down on genomic stability. Colony 
forming assays with GFP+/lin- cells confirmed previous studies36 demonstrating that 
PML-RAR expression enhanced genome instability compared to wild-type cells 
(supplemental Figure 13).  Hdac1 knock-down amplified this phenomenon with more 
than 50% of metaphases being aneuploid after in vitro plating (Figure 3D).   
To confirm the specificity of the Hdac1 knock-down effects, PML-RAR-expressing 
lin-/Hdac1-kd cells were super-infected with a retrovirus expressing Hdac1 cDNA 
that could not be targeted by the RNAi knock-down constructs (supplemental Figure 
14A). Strikingly, expression of non-targetable Hdac1 essentially abolished the 
differentiation block observed upon Hdac1 knock-down, confirming that the observed 
phenotype was due to the selective loss of the protein (supplemental Figure 14B-C). 
Taken together, these results indicate that down-regulation of Hdac1 potentiates the 
effects of PML-RAR on differentiation and genomic stability of hematopoietic 
progenitors, consistent with the observed acceleration of leukemogenesis in vivo.  
 
Hdac1 knock-down primes the expansion of the prospective leukemic initiating 
cell compartment at the pre-leukemic stage  
To determine the effect of Hdac1 knock-down on the differentiation of pre-leukemic 
myeloid cells in vivo, irradiated recipient mice were reconstituted with PML-RAR-
expressing GFP+/lin-/Hdac1-kd and GFP+/lin-/CTRL cells, and bone marrows from 
transplanted mice were analysed at different time points during the pre-leukemic 
phase (supplemental Figure 15). Knock-down of Hdac1 caused a dramatic expansion 
 For personal use only. by Pier Guiseppe Pelicci on March 26, 2013. bloodjournal.hematologylibrary.orgFrom 
 17 
of immature Gr-1+/c-Kit+ cells and a decrease in expression of Mac-1 (Figure 4A-B). 
As a consequence of the expansion of Gr-1+/c-Kit+/Mac-1low cells, we observed an 
imbalance in lineage distribution following knock-down of Hdac1 in pre-leukemic 
APL mice, with a shift towards the myeloid lineage at the expense of the lymphoid 
compartment (Figure 4A, supplemental Table 3). Consistent with their expansion, the 
proliferative ability in vivo of PML-RAR-expressing Gr-1+/c-Kit+/Hdac1-kd cells was 
strongly enhanced compared to CTRL cells as assessed by BrdU incorporation 
(Figure 4C). This effect was confirmed in vitro, as shown by the increase in colony 
forming cells in serial methylcellulose assays (Figure 4D). In addition, when cultured 
in methylcellulose supplemented with a pro-differentiation cytokine cocktail, PML-
RAR expressing Gr-1+/c-Kit+/Hdac1-kd cells maintained their undifferentiated 
phenotype which lasted for several platings, while PML-RAR-expressing CTRL cells 
showed an activated differentiation program (Figure 4E). Intriguingly, in frankly 
leukemic mice it has been shown that the leukemic stem cell compartment is enriched 
in Gr-1+/c-Kit+ cells37,38. We therefore transplanted PML-RAR-expressing Gr-1+/c-
Kit+/Hdac1-kd cells from pre-leukemic mice into secondary recipient mice, which 
developed APL (supplemental Figure 16).  Taken together, these results show that 
during the pre-leukemic stage Hdac1 functions to prevent the expansion of a PML-
RAR-expressing cell sub-population prototypic of the leukemic stem cell 
compartment in the leukemic stage, that is able to give rise to APL. 
 
Hdac1 knock-down has an antitumor activity on APL cells at the leukemic stage 
Our results are apparently at odds with the known anti-tumor effects of HDACi, 
shown in several contexts, including leukemias expressing the PML-RAR 
oncoprotein30. We therefore knocked-down Hdac1 (or luciferase as a control: CTRL) 
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in frankly leukemic APL cells16 (Figure 5A-B) and observed concomitant induction of 
Hdac2 expression and increased histone acetylation (Figure 5B). GFP+/Hdac1-kd and 
GFP+/CTRL APL cells were transplanted into syngeneic recipient mice and in 
contrast to the accelerated tumorigenesis observed following knock-down of Hdac1 in 
pre-leukemic cells, Hdac1 depletion caused an increased overall survival of the 
recipient mice (Figure 5C). Consistent with this result and as previously observed 
24,30
, treatment with the class I HDAC inhibitor Valproic acid (VPA) 39,40 caused an 
increased overall survival of frankly leukemic APL mice (Figure 5D and 
supplemental Figure 17). 
These results suggest that Hdac1 activity plays opposing roles at different stages of 
APL development: it antagonizes the oncogenic activity of PML-RAR at the pre-
leukemic stage, while favouring the growth of the leukemic mass in the overt 
leukemic state. 
 
Pharmacological inhibition of class I HDACs mimics the phenotype of Hdac1 
knock-down 
We then determined if the biological effect of Hdac1 knock-down in PML-RAR-
expressing pre-leukemic cells could be phenocopied by inhibiting HDACs 
pharmacologically. Strikingly, short-term treatment with VPA doubled the number of 
Gr-1+/c-Kit+ cells in the bone marrow of pre-leukemic mice (Figure 6A, left panel). 
Bone marrow cells derived from VPA-treated mice gave rise to a higher number of 
colonies than cells derived from untreated mice (Figure 6A, right panel). Importantly, 
VPA-treated mice developed leukemia within a shorter period compared to untreated 
mice (Figure 6C, supplemental Table 1D). Taken together, these results show that 
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pharmacological inhibition of HDAC enzymatic activity in pre-leukemic mice mimics 
the oncogenic effects of Hdac1 knock-down. 
Discussion 
Here, we show in different mouse tumor models (APL, p53-/- and myc-driven 
lymphomas) that one putative barrier to full transformation is surprisingly provided 
by class I Hdacs 1 and 2. Knock-down of Hdac1 potentiated both the block of cellular 
differentiation, and the increased genomic instability mediated by PML-RAR in 
hematopoietic progenitors. Either or both biological deregulations could be sufficient 
to cooperate with the tumor-promoting activities of oncoproteins such as PML-RAR 
and Myc and would provide a functional explanation for the observed increase in 
frequency of transformation to full leukemia in Hdac1-deficient cells. Additionally, 
and potentially linked to those events, we observed in Hdac1-deficient pre-leukemic 
cells a dramatic expansion of a subpopulation of myeloid precursor cells (Gr1+ and c-
Kit+ cells) that represents the major source of leukemic stem cells in the full leukemic 
stage37,38. We hypothesize that in pre-leukemia this subpopulation acts as a reservoir 
of target cells for full leukemic transformation: in the presence of decreased levels of 
Hdac1, expansion of Gr1+/c-Kit+ cells leads to an increase in the number of candidate 
target cells and of the probability of transformation, thus accelerating 
leukemogenesis. These results are reminiscent of the role of histone H3K9 
methylation in the tumor-suppression of Ras and myc-driven lymphoma development 
in transgenic mice41, and support an important role for heterochromatin as a tumor 
suppressive mechanism41-43. Consistent with the notion that HDACs can function as 
tumor suppressors, Hdac1 and Hdac2 mRNA levels were found to be selectively 
reduced in human AML samples, suggesting that this function may be important in 
human leukemogenesis. 
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HDACs have been widely considered to have tumor-promoting and/or sustaining 
roles especially given the impressive anti-tumor responses mediated by HDACi in 
certain hematological malignancies7. Indeed, combined genetic deletion of Hdac1 and 
Hdac2 results in the activation of a senescent program, and/or mitotic catastrophe and 
death of transformed cells5,6. Here, we showed that knock-down of Hdac1 in 
transplanted PML-RAR-expressing leukemia cells prolonged the survival of recipient 
mice, supporting the view that Hdac1 has oncogenic activity in established tumor 
cells.  As a potential explanation to reconcile the opposing roles of Hdac1 unraveled 
in APL, we speculate that Hdac1 may have distinct functions in different leukemia 
subpopulations: indeed, VPA treatment induces differentiation and death of APL 
blasts, sparing the leukemic stem cell compartment.24 
Short-term in vivo treatment of pre-leukemic mice with the class I HDACi VPA 
phenocopied the effect of Hdac1 knock-down during PML-RAR-mediated 
leukemogenesis with expansion of Gr1+/c-Kit+ population and accelerated disease. 
Intriguingly, this phenomenon was not observed following treatment of pre-malignant 
Eμ-myc mice with VPA, indicating that a tumor-type or oncogene-specific effect may 
be at play (data not shown). Nevertheless, these results are somewhat unsettling 
concerning the growing clinical use of HDACi. The broad inhibition of multiple 
HDACs by most available HDACi has been proposed as a potential explanation for 
the lack of sustained efficacy of these agents in most cancer patients. Our data suggest 
that HDAC inhibition may block intrinsic anti-tumor functions of HDACs, and imply 
that more studies are needed to systematically dissect the role of individual HDACs, 
at different stages of tumorigenesis, in different tumor compartments and in different 
tumor cell types.   
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Figure legends 
 
Figure 1: Hdac1 knock-down accelerates APL development. 
A) Immunoblot analysis of Hdac1, 2 and 3 expression, and histone H3/H4 acetylation 
in GFP+ lin- cells derived from mCGPR/PR mice and transduced with the indicated 
retroviral vectors. Total histone H3 served as loading control. B) Leukemia-free 
survival curves of mice transplanted with the indicated GFP+ lin- cells. HDAC1-KDA 
and HDAC1-KDB indicate two different shRNA against Hdac1 (supplemental Table 
4). CTRL vs Hdac1: p<0.0001. C) Hdac1, Hdac2 and Hdac3 expression in bone 
marrows of leukemic mice. Vinculin was used as loading control. D) Cytological 
analysis of APL blasts from spleens of moribund animals. Original magnification 
1000X, May Grunwal-Giemsa staining, Olympus BX51 E) Representative 
immunophenotype of leukemic cells derived from spleens of moribund animals.  
 
Figure 2: Hdac1/2 knock-down accelerates lymphomagenesis. 
A-B) Lin- cells from p53-/- mice transduced with the control vector (CTRL) or vectors 
carrying a shRNA against Hdac1 or Hdac2 were sorted for GFP positivity and 
injected into lethally irradiated recipient WT mice. A) Immunoblot analysis of cells 
transduced with the indicated retroviral vectors. The arrow indicates HDAC2. The 
asterisk indicates HDAC1 residual staining from the previous immunoblotting assay. 
Hdac3 served as loading control. B) Leukemia-free survival curves of mice 
transplanted with p53 null lin- cells transduced with the control vector (CTRL) or a 
vector carrying a shRNA against Hdac1 (left panel, p<0.05) or Hdac2 (right panel, 
p=ns).  C-D) Eμ-myc fetal liver progenitor cells were transduced with the control 
vector (CTRL) or vectors carrying a shRNA against Hdac1 or Hdac2 and injected into 
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irradiated recipient PTPRCA mice. C) Kaplan-Meier survival curves are shown; 
hdac1 p<0.05, hdac2 p=ns. D) Western blots were performed on FACS sorted GFP+ 
cell lysates from a control spontaneous Eμ-myc lymphoma (lane 1) and the 
indicated primary lymphomas with knockdown of HDAC1 (lanes 2 and 3) or HDAC2 
(lanes 4-6) and analyzed  for the expression  of the indicated HDACs. B-actin was 
used as loading control.  
 
Figure 3. Hdac1 knock-down enhances the myeloid differentiation block and 
genomic instability imposed by PML-RAR in lin- cells derived from mCGPR/PR 
mice. 
Lin- cells were transduced with the indicated vectors, sorted for GFP positivity, and 
plated in methylcellulose-containing medium. A-B) Analysis of the expression of the 
indicated differentiation markers in control and Hdac1 knock-down pre-leukemic 
cells. A representative dot plot (A) and the statistical analysis of 3 independent 
experiments (B) are shown. C) Analysis of the proliferative potential of control and 
Hdac1 knock-down pre-leukemic cells by serial replating assay. D) Plot of the 
percentages of aneuploid and diploid cells in methaphase spreads from CTRL (n=82) 
and HDAC1-KD (n=76) cells. The statistical analysis was performed by Fisher's exact 
test (GraphPad software). 
 
Figure 4. Hdac1 knock-down primes the expansion of Gr-1+/c-Kit+ cells in vivo. 
Lin- cells derived from mCGPR/PR transgenic mice were transduced with the indicated 
vectors, and sorted GFP+ cells were injected into lethally irradiated mice. Mice were 
sacrificed 30 days post transplantation, and their phenotype was analyzed. A) A 
representative dot plot showing the levels of the indicated differentiation markers in 
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bone marrow cells. Insets show the cytological analysis of the sorted subpopulations 
(red squares).  B) Plot of the levels of Gr-1+/c-Kit+ cells in the indicated murine bone 
marrow samples. C) Mice transplanted with the indicated cells were injected with 
BrdU. In the graph, the levels of BrdU incorporation are shown. D) The indicated Gr-
1+/c-Kit+ cells were plated in methylcellulose medium and scored for colony forming 
ability. In the graph, the mean and standard deviation of 3 independent experiments 
are shown. E) Morphological analysis of the indicated Gr-1+/c-Kit+ cells, harvested 
after plating in methylcellulose medium. Left panels, representative cytospins; right 
panel, percentage of mature and immature cells, original magnification 1000X, May 
Grunwal-Giemsa staining, Olympus BX51. Statistical analysis was performed using 
Fisher's exact test.  
 
Figure 5. Hdac1 knock-down in APL blasts increases mice survival. 
A-C) APL blasts from 129sv mice were trandusced with the indicated vectors, sorted 
for GFP positivity and tranplanted in wt mice. A) Analysis of Hdac1 mRNA levels in 
APL blasts transduced with the indicated retroviral vectors. Values are normalized 
against GAPDH and referred to CTRL. The graph represents the average and standard 
deviation of three independent experiments. B) Immunoblot analysis of the expression 
of Hdac1, 2 and 3 and histone H3 acetylation in GFP+ APL blasts transduced as 
indicated. Histone H3 served as loading control. C) Leukemia-free survival curves of 
mice transplanted with APL blasts transduced with the indicated vectors, and then 
sorted for GFP expression (CTRL vs HDAC1-KDA or CTRL vs HDAC1-KDB: 
p<0.05). D) Leukemia-free survival curves of C57Bl/6-Ly5.1 recipient mice 
transplanted with APL cells derived from the mCGPR/PR leukemic mouse #1.VPA 
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treatment  was started when the blast cells in peripheral blood reached 5–10%. CTRL 
vs VPA: p<0.001. Day 0 indicates the start of the treatment. 
 
Figure 6: VPA treatment mimics the phenotype of Hdac1 knock-down in vivo. 
mCGPR/PR mice were treated with VPA or PBS (CTRL) for 14 days and then A) 
twelve hours after the last injection, mice were sacrificed, bone marrows collected 
and analysed for the expression of Gr-1 and c-Kit (left panel), or colony forming 
ability (right panel)., or B) followed for leukemia development. In the graph, 
leukemia-free survival curves from VPA and PBS treated mice; p<0.05. 
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